EA202091653A1 - Миноциклин для лечения воспалительных заболеваний кожи - Google Patents

Миноциклин для лечения воспалительных заболеваний кожи

Info

Publication number
EA202091653A1
EA202091653A1 EA202091653A EA202091653A EA202091653A1 EA 202091653 A1 EA202091653 A1 EA 202091653A1 EA 202091653 A EA202091653 A EA 202091653A EA 202091653 A EA202091653 A EA 202091653A EA 202091653 A1 EA202091653 A1 EA 202091653A1
Authority
EA
Eurasian Patent Office
Prior art keywords
minocycline
inflammatory skin
treatment
skin diseases
skin disease
Prior art date
Application number
EA202091653A
Other languages
English (en)
Russian (ru)
Inventor
Свати Кулкарни
Биджай Кумар Падхи
Шавас Аликунджу
Раджеев Сингх Рагхуванши
Сринивас Рамчандра Сидгидди
Анирудх Гаутам
Original Assignee
Д-Р Редди'С Лабораторис Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65269058&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA202091653(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Д-Р Редди'С Лабораторис Лтд. filed Critical Д-Р Редди'С Лабораторис Лтд.
Publication of EA202091653A1 publication Critical patent/EA202091653A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EA202091653A 2018-01-07 2019-01-07 Миноциклин для лечения воспалительных заболеваний кожи EA202091653A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201741023993 2018-01-07
PCT/IB2019/000144 WO2019135166A1 (en) 2018-01-07 2019-01-07 Minocycline for treating inflammatory skin conditions

Publications (1)

Publication Number Publication Date
EA202091653A1 true EA202091653A1 (ru) 2020-12-23

Family

ID=65269058

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202091653A EA202091653A1 (ru) 2018-01-07 2019-01-07 Миноциклин для лечения воспалительных заболеваний кожи

Country Status (11)

Country Link
US (5) US11191740B2 (cg-RX-API-DMAC7.html)
EP (1) EP3735249A1 (cg-RX-API-DMAC7.html)
JP (3) JP7561029B2 (cg-RX-API-DMAC7.html)
KR (1) KR102705507B1 (cg-RX-API-DMAC7.html)
CN (1) CN111818927A (cg-RX-API-DMAC7.html)
AU (2) AU2019205134B9 (cg-RX-API-DMAC7.html)
BR (1) BR112020013789A2 (cg-RX-API-DMAC7.html)
CA (1) CA3087838A1 (cg-RX-API-DMAC7.html)
EA (1) EA202091653A1 (cg-RX-API-DMAC7.html)
MX (1) MX2020007222A (cg-RX-API-DMAC7.html)
WO (1) WO2019135166A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020007222A (es) 2018-01-07 2020-12-10 Dr Reddys Laboratories Ltd Metodos para el tratamiento de afecciones inflamatorias de la piel.
WO2020018859A1 (en) 2018-07-19 2020-01-23 Clark Equipment Company Display position for cab with overhead door
US20260216213A1 (en) * 2024-11-01 2026-07-30 Journey Medical Corporation Methods for treating rosacea
CN120324439A (zh) * 2025-03-05 2025-07-18 福安药业集团宁波天衡制药有限公司 一种稳定的盐酸米诺环素胶囊及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7211267B2 (en) 2001-04-05 2007-05-01 Collagenex Pharmaceuticals, Inc. Methods of treating acne
EP1716856A3 (en) * 2001-04-05 2009-02-18 Collagenex Pharmaceuticals, Inc. The treatment of acne
WO2003088906A2 (en) 2002-04-16 2003-10-30 Collagenex Pharmaceuticals, Inc. Methods of simultaneously treating ocular rosacea and acne rosacea
US20080242642A1 (en) 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US8252776B2 (en) 2007-04-02 2012-08-28 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
US7919483B2 (en) 2005-06-24 2011-04-05 Medicis Pharmaceutical Corporation Method for the treatment of acne
US20080241235A1 (en) * 2007-04-02 2008-10-02 Medicis Pharmaceutical Corporation Minocycline oral dosage forms for the treatment of acne
AU2010302350B2 (en) 2009-10-02 2015-06-18 Journey Medical Corporation Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US20140186269A1 (en) 2013-01-03 2014-07-03 Foamix Ltd. Vehicle compositions essentially free of pharmaceutically active agents for the improved treatment of acne and related disorders
PT106679B (pt) 2012-11-27 2015-03-25 Hovione Farmaciencia Sa Formulações tópicas de tetraciclinas, sua preparação e usos
MX2020007222A (es) 2018-01-07 2020-12-10 Dr Reddys Laboratories Ltd Metodos para el tratamiento de afecciones inflamatorias de la piel.

Also Published As

Publication number Publication date
RU2020125984A (ru) 2022-02-07
US20210121420A1 (en) 2021-04-29
JP2026031656A (ja) 2026-02-24
US20260191804A1 (en) 2026-07-09
KR102705507B1 (ko) 2024-09-10
AU2019205134B2 (en) 2024-11-07
US20230131030A1 (en) 2023-04-27
RU2020125984A3 (cg-RX-API-DMAC7.html) 2022-02-07
WO2019135166A9 (en) 2020-07-16
US20190209500A1 (en) 2019-07-11
CN111818927A (zh) 2020-10-23
MX2020007222A (es) 2020-12-10
CA3087838A1 (en) 2019-07-11
US10905664B2 (en) 2021-02-02
AU2019205134B9 (en) 2025-02-20
AU2019205134A1 (en) 2020-08-20
KR20200108018A (ko) 2020-09-16
JP2021509409A (ja) 2021-03-25
AU2025200826A1 (en) 2025-02-27
JP2024098011A (ja) 2024-07-19
US12594252B2 (en) 2026-04-07
JP7561029B2 (ja) 2024-10-03
WO2019135166A1 (en) 2019-07-11
US20200222345A1 (en) 2020-07-16
US11364212B2 (en) 2022-06-21
AU2019205134A2 (en) 2020-08-20
EP3735249A1 (en) 2020-11-11
US11191740B2 (en) 2021-12-07
BR112020013789A2 (pt) 2021-02-17

Similar Documents

Publication Publication Date Title
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
AR101740A1 (es) Terapia de combinación y composiciones
EA201690754A1 (ru) Применение ингибитора pcsk9 для лечения гиперлипидемии
JOP20200031A1 (ar) طرق لعلاج الالتهاب العظمي المفصلي باستخدام هلام من كانابيديول عبر الأدمة
AR105712A1 (es) Composiciones de insulina de rápida acción
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
MY209831A (en) Methods of using a bispecific antibody that recognizes coagulation factor ix and/or activated coagulation factor ix and coagulation factor x and/or activated coagulation factor x
MX2014000555A (es) Agentes que se unen a las proteinas de r-espondinas (rspo) y usos de los mismos.
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
EA202091446A1 (ru) Способы лечения хронических воспалительных заболеваний
EA201692481A1 (ru) Комбинация, содержащая глюкокортикоид и edo-s101
PH12020550462A1 (en) Cocrystals, pharmaceutical compositions thereof, and methods of treatment involving same
MX2021000340A (es) Nuevos compuestos.
CY1122508T1 (el) Παρασκευευασματα για θεραπεια gd2 θετικου καρκινου
MX2017002825A (es) Tratamientos medicos a base de anamorelina.
EA201691656A2 (ru) Терапевтические способы с применением норибогаина и родственных соединений
EP3922264A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION, IMPROVEMENT OR TREATMENT OF SKIN DISEASES
MX2020007222A (es) Metodos para el tratamiento de afecciones inflamatorias de la piel.
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
BR112016023011A2 (pt) tratamento de câncer gástrico
MY186840A (en) Method for treating psoriasis patient which received anti-tnf-alpha antibody therapy
EA201990550A1 (ru) Офтальмологический препарат, включающий азоловое соединение
ZA202002107B (en) Use of specific sirna against protein s for the treatment of hemophilia
BR112015028334A2 (pt) agente e método para o tratamento de herpes